Hi GaryV,
You know I am a retired psychiatrist and have nothing to do with any pharmaceutical companies - as a matter of fact I am very afraid of drugs due to the adverse effects.
There are not many studies of Vidaza in low risk patients - most studies with about 50 % improved patients were done in high risk patients - probably that's why the results are better in this study with many low risk patients.
Many reseachers report that for the moment Vidaza is the first line drug for MDS patients (except patients with the 5q- that often respond to Revlimid):
http://docs.google.com/viewer?a=v&q=...8ykxnGBZeG32MQ
Actually Dacogen is not approved in EU because they have not yet showed that the drug is better that best supportive care for high risk MDS patients. Probably that is because they have not tested the best way to adinistrate the drug. We all know that MDS is not one disease but many and some patients that don't respond to Vidaza improve when they get Dacogen.
Kind regards
Birgitta-A